Role of the LytSR two-component regulatory system in adaptation to cationic antimicrobial peptides in staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 8, 2013, Pages 3875-3882

  Yang, Soo Jin ^a,b   Xiong, Yan Q ^a,b   Yeaman, Michael R ^a,b   Bayles, Kenneth W ^c   Abdelhady, Wessam ^a   Bayer, Arnold S ^a,b  

^a LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; BACTERIAL PROTEIN; CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; DAPTOMYCIN; NEUROMUSCULAR DEPOLARIZING AGENT; THROMBIN;

ADAPTATION; APOPTOSIS; ARTICLE; BACTERIAL STRAIN; CELL MEMBRANE; CYTOLYSIS; ENDOCARDITIS; IN VITRO STUDY; NEUTROPHIL; NONHUMAN; OPERON; PLASMID; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; TISSUE SURVIVAL;

ADAPTATION, BIOLOGICAL; AMINOACYLTRANSFERASES; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL PROTEINS; CARBONYL CYANIDE M-CHLOROPHENYL HYDRAZONE; DAPTOMYCIN; DRUG EVALUATION, PRECLINICAL; ENDOCARDITIS, BACTERIAL; FEMALE; GENE KNOCKOUT TECHNIQUES; GENES, BACTERIAL; GENETIC COMPLEMENTATION TEST; MEMBRANE POTENTIALS; MEMBRANE PROTEINS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; OPERON; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84880281986     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00412-13     Document Type: Article

References (60)

1. Peschel A. 2002. How do bacteria resist human antimicrobial peptides?. Trends Microbiol. 10:179-186.
2. Voyich JM, Braughton KR, Sturdevant DE, Whitney AR, Said-Salim B, Porcella SF, Long RD, Dorward DW, Gardner DJ, Kreiswirth BN, Musser JM, DeLeo FR. 2005. Insights into mechanisms used by Staphylococcus aureus to avoid destruction by human neutrophils. J. Immunol. 175:3907-3919.
3. Bader MW, Sanowar S, Daley ME, Schneider AR, Cho U, Xu W, Klevit RE, Le Moual H, Miller SI. 2005. Recognition of antimicrobial peptides by a bacterial sensor kinase. Cell 122:461-472.
4. Brogden KA. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. Nat. Rev. Microbiol. 3:238-250.
5. Peschel A, Jack RW, Otto M, Collins LV, Staubitz P, Nicholson G, Kalbacher H, Nieuwenhuizen WF, Jung G, Tarkowski A, van Kessel KPM, van Strijp JAG. 2001. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine. J. Exp. Med. 193:1067-1076.
6. Xiong YQ, Hady WA, Bayer AS, Chen L, Kreiswirth BN, Yang S-J. 2012. Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 56:5528-5533.
7. Koo S-P, Bayer AS, Yeaman MR. 2001. Diversity in antistaphylococcal mechanisms among membrane-targeting antimicrobial peptides. Infect. Immun. 69:4916-4922.
8. Rice KC, Firek BA, Nelson JB, Yang Patton S-JTG, Bayles KW. 2003. The Staphylococcus aureus cidAB operon: evaluation of its role in regulation of murein hydrolase activity and penicillin tolerance. J. Bacteriol. 185:2635-2643.
9. Li M, Lai Y, Villaruz AE, Cha DJ, Sturdevant DE, Otto M. 2007. Gram-positive three-component antimicrobial peptide-sensing system. Proc. Natl. Acad. Sci. U. S. A. 104:9469-9474.
10. Patton TG, Bayles KW, Yang S-J. 2006. The role of proton motive force in expression of the Staphylococcus aureus cid and lrg operons. Mol. Microbiol. 59:1395-1404.
11. Sharma-Kuinkel BK, Mann EE, Ahn JS, Kuechenmeister LJ, Dunman PM, Bayles KW. 2009. The Staphylococcus aureus LytSR two-component regulatory system affects biofilm formation. J. Bacteriol. 191:4767-4775.
12. Sadykov MR, Bayles KW. 2012. The control of death and lysis in staphylococcal biofilms: a coordination of physiological signals. Curr. Opin. Microbiol. 15:211-215.
13. Mann EE, Rice KC, Boles BR, Endres JL, Ranjit D, Chandramohan L, Tsang LH, Smeltzer MS, Horswill AR, Bayles KW. 2009. Modulation of eDNA release and degradation affects Staphylococcus aureus biofilm maturation. PLoS One 4:e5822. doi:10.1371/journal.pone.0005822.
14. Rice KC, Bayles KW. 2003. Death's toolbox: examining the molecular components of bacterial programmed cell death. Mol. Microbiol. 50:729.
15. Groicher KH, Firek BA, Fujimoto DF, Bayles KW. 2000. The Staphylococcus aureus lrgAB operon modulates murein hydrolase activity and penicillin tolerance. J. Bacteriol. 182:1794-1801.
16. Gillaspy AF, Hickmon SG, Skinner RA, Thomas JR, Nelson CL, Smeltzer MS. 1995. Role of the accessory gene regulator (agr) in pathogenesis of staphylococcal osteomyelitis. Infect. Immun. 63:3373-3380.
17. Silverman JA, Perlmutter NG, Shapiro HM. 2003. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:2538-2544.
18. Steenbergen JN, Alder J, Thorne GM, Tally FP. 2005. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J. Antimicrob. Chemother. 55:283-288.
19. Xiong YQ, Bayer AS, Elazegui L, Yeaman MR. 2006. A synthetic congener modeled on a microbicidal domain of thrombin-induced platelet microbicidal protein-1 recapitulates staphylocidal mechanisms of the native molecule. Antimicrob. Agents Chemother. 50:3786-3792.
20. Yeaman MR, Gank KD, Bayer AS, Brass EP. 2002. Synthetic peptides that exert antimicrobial activities in whole blood and blood-derived matrices. Antimicrob. Agents Chemother. 46:3883-3891.
21. Yeaman MR, Bayer AS, Koo SP, Foss W, Sullam PM. 1998. Platelet microbicidal proteins and neutrophil defensin disrupt the Staphylococcus aureus cytoplasmic membrane by distinct mechanisms of action. J. Clin. Invest. 101:178-187.
22. Yeaman MR, Puentes SM, Norman DC, Bayer AS. 1992. Partial characterization and staphylocidal activity of thrombin-induced platelet microbicidal protein. Infect. Immun. 60:1202-1209.
23. Yeaman MR, Sullam PM, Dazin PF, Bayer AS. 1994. Platelet microbicidal protein alone and in combination with antibiotics reduces Staphylococcus aureus adherence to platelets in vitro. Infect. Immun. 62:3416-3423.
24. Xiong YQ, Mukhopadhyay K, Yeaman MR, Adler-Moore J, Bayer AS. 2005. Functional interrelationships between cell membrane and cell wall in antimicrobial peptide-mediated killing of Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3114-3121.
25. Jones T, Yeaman MR, Sakoulas G, Yang SJ, Proctor RA, Sahl HG, Schrenzel J, Xiong YQ, Bayer AS. 2008. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob. Agents Chemother. 52:269-278.
26. Mishra NN, Liu GY, Yeaman MR, Nast CC, Proctor RA, McKinnell J, Bayer AS. 2011. Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides. Antimicrob. Agents Chemother. 55:526-531.
27. Mishra NN, Yang SJ, Sawa A, Rubio A, Nast CC, Yeaman MR, Bayer AS. 2009. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus (MRSA). Antimicrob. Agents Chemother. 53:2312-2318.
28. Mukhopadhyay K, Whitmire W, Xiong YQ, Molden J, Jones T, Peschel A, Staubitz P, Adler-Moore J, McNamara PJ, Proctor RA, Yeaman MR, Bayer AS. 2007. In vitro susceptibility of Staphylococcus aureus to thrombin-induced platelet microbicidal protein-1 (tPMP-1) is influenced by cell membrane phospholipid composition and asymmetry. Microbiology 153: 1187-1197.
29. Bayer AS, Prasad R, Chandra J, Koul A, Smriti M, Varma A, Skurray RA, Firth N, Brown MH, Koo SP, Yeaman MR. 2000. In vitro resistance of Staphylococcus aureus to thrombin-induced platelet microbicidal protein is associated with alterations in cytoplasmic membrane fluidity. Infect. Immun. 68:3548-3553.
30. Chambers HF, Basuino L, Diep BA, Steenbergen J, Zhang S, Tattevin P, Alder J. 2009. Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis. Antimicrob. Agents Chemother. 53:1463-1467.
31. Brunskill EW, Bayles KW. 1996. Identification and molecular characterization of a putative regulatory locus that affects autolysis in Staphylococcus aureus. J. Bacteriol. 178:611-618.
32. Yeaman MR, Yount NY. 2003. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 55:27-55.
33. Meehl M, Herbert S, Gotz F, Cheung A. 2007. Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 51:2679-2689.
34. Peschel A, Otto M, Jack RW, Kalbacher H, Jung G, Gotz F. 1999. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J. Biol. Chem. 274:8405-8410.
35. Yang S-J, Nast CC, Mishra NN, Yeaman MR, Fey PD, Bayer AS. 2010. Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob. Agents Chemother. 54:3079-3085.
36. Li M, Cha DJ, Lai Y, Villaruz AE, Sturdevant DE, Otto M. 2007. The antimicrobial peptide-sensing system aps of Staphylococcus aureus. Mol. Microbiol. 66:1136-1147.
37. Yang S-J, Bayer AS, Mishra NN, Meehl M, Ledala N, Yeaman MR, Xiong YQ, Cheung AL. 2012. The Staphylococcus aureus two-component regulatory system, GraRS, senses and confers resistance to selected cationic antimicrobial peptides. Infect. Immun. 80:74-81.
38. Yang SJ, Kreiswirth BN, Sakoulas G, Yeaman MR, Xiong YQ, Sawa A, Bayer AS. 2009. Enhanced expression of dltABCD is associated with development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J. Infect. Dis. 200:1916-1920.
39. Yang SJ, Xiong YQ, Dunman PM, Schrenzel J, Francois P, Peschel A, Bayer AS. 2009. Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 53:2636-2637.
40. Bertsche U, Weidenmaier C, Kuehner D, Yang SJ, Baur S, Wanner S, Francois P, Schrenzel J, Yeaman MR, Bayer AS. 2011. Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with in-creased cell wall teichoic acid production and D-alanylation. Antimicrob. Agents Chemother. 55:3922-3928.
41. Weidenmaier C, Peschel A, Kempf VAJ, Lucindo N, Yeaman MR, Bayer AS. 2005. DltABCD-and MprF-mediated cell envelope modifications of Staphylococcus aureus confer resistance to platelet microbicidal proteins and contribute to virulence in a rabbit endocarditis model. Infect. Immun. 73:8033-8038.
42. Weidenmaier C, Peschel A, Xiong YQ, Kristian SA, Dietz K, Yeaman MR, Bayer AS. 2005. Lack of wall teichoic acids in Staphylococcus aureus leads to reduced interactions with endothelial cells and to attenuated virulence in a rabbit model of endocarditis. J. Infect. Dis. 191:1771-1777.
43. Xiong Y-Q, Kupferwasser LI, Zack PM, Bayer AS. 1999. Comparative efficacies of liposomal amikacin (MiKasome) plus oxacillin versus conventional amikacin plus oxacillin in experimental endocarditis induced by Staphylococcus aureus: microbiological and echocardiographic analyses. Antimicrob. Agents Chemother. 43:1737-1742.
44. Rose WE, Rybak MJ, Kaatz GW. 2007. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J. Antimicrob. Chemother. 60:334-340.
45. Xiong YQ, Fowler JVG, Yeaman MR, Perdreau-Remington F, Kreiswirth BN, Bayer AS. 2009. Phenotypic and genotypic characteristics of persistent methicillin-resistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model. J. Infect. Dis. 199:201-208.
46. Rice KC, Nelson JB, Patton TG, Yang SJ, Bayles KW. 2005. Acetic acid induces expression of the Staphylococcus aureus cidABC and lrgAB murein hydrolase regulator operons. J. Bacteriol. 187:813-821.
47. Xiong Y-Q, Bayer AS, Yeaman MR, van Wamel W, Manna AC, Cheung AL. 2004. Impacts of sarA and agr in Staphylococcus aureus strain Newman on fibronectin-binding protein A gene expression and fibronectin adherence capacity in vitro and in experimental infective endocarditis. Infect. Immun. 72:1832-1836.
48. Yang S-J, Xiong YQ, Boyle-Vavra S, Daum R, Jones T, Bayer AS. 2010. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillinresistant Staphylococcus aureus with evolving oxacillin susceptibility (the seesaw effect). Antimicrob. Agents Chemother. 54:3161-3169.
49. Hancock REW, Diamond G. 2000. The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol. 8:402-410.
50. Pelegrini P, Farias L, Saude A, Costa F, Bloch C, Silva L, Oliveira A, Gomes C, Sales M, Franco O. 2009. A novel antimicrobial peptide from Crotalaria pallida seeds with activity against human and phytopathogens. Curr. Microbiol. 59:400-404.
51. Welling MM, Hiemstra PS, van den Barselaar MT, Paulusma-Annema A, Nibbering PH, Pauwels EKJ, Calame W. 1998. Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation. J. Clin. Invest. 102: 1583-1590.
52. Alborn WE, Jr, Allen NE, Preston DA. 1991. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob. Agents Chemother. 35:2282-2287.
53. Koo SP, Yeaman MR, Nast CC, Bayer AS. 1997. The cytoplasmic membrane is a primary target for the staphylocidal action of thrombin-induced platelet microbicidal protein. Infect. Immun. 65:4795-4800.
54. Beenken KE, Spencer H, Griffin LM, Smeltzer MS. 2012. Impact of extracellular nuclease production on the biofilm phenotype of Staphylococcus aureus under in vitro and in vivo conditions. Infect. Immun. 80: 1634-1638.
55. Rice KC, Mann EE, Endres JL, Weiss EC, Cassat JE, Smeltzer MS, Bayles KW. 2007. The cidA murein hydrolase regulator contributes to DNA release and biofilm development in Staphylococcus aureus. Proc. Natl. Acad. Sci. U. S. A. 104:8113-8118.
56. Staubitz P, Neumann H, Schneider T, Wiedemann I, Peschel A. 2004. MprF-mediated biosynthesis of lysylphosphatidylglycerol, an important determinant in staphylococcal defensin resistance. FEMS Microbiol. Lett. 231:67.
57. Sørensen O, Arnljots K, Cowland JB, Bainton DF, Borregaard N. 1997. The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood 90:2796-2803.
58. Ganz T. 1987. Extracellular release of antimicrobial defensins by human polymorphonuclear leukocytes. Infect. Immun. 55:568-571.
59. von Eiff C, Becker K, Machka K, Stammer H, Peters G. 2001. Nasal carriage as a source of Staphylococcus aureus bacteremia. N. Engl. J. Med. 344:11-16.
60. Ganz T, Selsted ME, Lehrer RI. 1990. Defensins. Eur. J. Haematol. 44:1-8.